Core Insights - Quantum BioPharma Ltd. has signed an agreement with a global pharmaceutical contract research organization to prepare an IND application package for Lucid-21-302 (Lucid-MS) with the US FDA, aiming to initiate a Phase 2 trial for multiple sclerosis (MS) [1][3] - Lucid-21-302 is a first-in-class, non-immunomodulatory, neuroprotective compound designed to prevent demyelination, a key factor in MS and other neurodegenerative diseases [2] - The company plans to submit the IND application to the FDA in Q4 2025, marking a significant step towards advancing its treatment for MS [3] Company Overview - Quantum BioPharma is focused on developing innovative biopharmaceutical solutions for neurodegenerative and metabolic disorders, with a lead compound, Lucid-MS, that has shown potential in preclinical models [4] - The company retains a 20.11% ownership stake in Celly Nutrition Corp., which is involved in the marketing of unbuzzd™, and has established a royalty agreement that includes 7% of sales until reaching $250 million, after which the royalty will drop to 3% [4] - Quantum BioPharma also maintains a portfolio of strategic investments through its subsidiary, FSD Strategic Investments Inc., which includes loans secured by residential or commercial property [4]